• - To determine the progression free survival of patients with metastatic transitional cell cancer treated with cisplatin, gemcitabine and bevacizumab. [ Time Frame: 36 months ] [ Designated as safety issue: No ]
  

• To estimate the time to event efficacy variables, including duration of response for responding patients, time to treatment failure and overall survival time [ Time Frame: 36 months ] [ Designated as safety issue: No ]
  
• To characterize the quantitative and qualitative toxicities of cisplatin gemcitabine and bevacizumab in this patient population. [ Time Frame: 36 months ] [ Designated as safety issue: Yes ]
  
• To estimate rate of partial response (PR), complete response (CR) and overall response (PR plus CR). [ Time Frame: 36 months ] [ Designated as safety issue: No ]
  

OUTLINE: This is a multi-center study.

• Cisplatin 70 mg/m2 Day 1
• Gemcitabine 1250 mg/m2 Day 1 and 8
• Bevacizumab 15 mg/kg Day 1

Review toxicity every cycle (every 3 weeks) Review for radiographic response every 2 cycles (every six weeks)

Progressive disease = off protocol therapy

Patients will be treated for up to a maximum of 8 cycles of cisplatin and gemcitabine (24 weeks of therapy). If a patient has not progressed by the end of 24 weeks (completion of cisplatin and gemcitabine), then patient will be treated with bevacizumab at 15 mg/kg every three weeks for a maximum of 12 months of bevacizumab therapy (since study entry).

If at any time patient has undue toxicity or progressive disease, patient will be removed from the study and followed until progression and for survival.

If the patient has Grade 3 or 4 neurotoxicity and/or the creatinine rises above 2.0, then the cisplatin will be discontinued and the patient continued on study and treated with gemcitabine and bevacizumab at the same dose and schedule.

ECOG Performance Status 0 or 1

Hematopoietic:

• White blood cell count > 3000/mm3
• Absolute neutrophil count (ANC) > 1500 mm/3
• Platelet count > 100,000/mm3
• Hemoglobin > 8 g/dL (may be transfused or receive erythropoietin support to maintain or exceed this level).
• INR < 1.5
• No full dose/therapeutic anticoagulation with either low molecular weight heparin or unfractionated heparin or coumadin

Hepatic:

• Total bilirubin of <1.5 mg/dL
• ALT <5 times upper limit of normal for subjects with documented liver metastases; <2.5 times the upper limit of normal for subjects without evidence of liver metastases.

Renal:

• Serum creatinine of < 1.5 mg/dL.
• Urine protein:creatinine ratio < 1.0 at screening

Cardiovascular:

• No history of myocardial infarction or stroke within the last 6 months
• No uncontrolled hypertension (blood pressure of >160 systolic and/or 110 diastolic mmHg on medication)
• No unstable angina, New York Heart Association (NYHA) Grade II or greater congestive heart failure
• No unstable symptomatic arrhythmia requiring medication (subjects with chronic atrial arrhythmia, i.e., atrial fibrillation or paroxysmal supraventricular tachycardia are eligible), or clinically significant peripheral vascular disease.

Pulmonary:

• Not specified